Literature DB >> 25024808

Hepatic failure induced by cyproterone acetate: A case report and literature review.

Jae Heon Kim1, Byung Wook Yoo2, Won Jae Yang1.   

Abstract

Cyproterone acetate (CPA) is an anti-androgenic drug that has been used to manage prostate cancer. The drug is well-tolerated, but has hepatotoxic effects. Hepatic failure induced by CPA is rare urologists tend to overlook its severity. We report a patient with metastatic prostate cancer who developed CPA-induced hepatic failure that manifested as bilirubinuria, which was initially misinterpreted as gross hematuria. The patient died despite receiving critical care. The aim of this study is to sound the alarm about CPA-induced hepatic failure.

Entities:  

Year:  2014        PMID: 25024808      PMCID: PMC4081269          DOI: 10.5489/cuaj.1753

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  15 in total

1.  Estrogen and cyproterone acetate combination-induced autoimmune hepatitis.

Authors:  Sabite Kacar; Meral Akdogan; Yasemin Koşar; Erkan Parlak; Nurgul Sasmaz; Perihan Oguz; Gulden Aydog
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062

2.  [Fatal subfulminant hepatitis caused by cyproterone acetate].

Authors:  M Antoni; M Bourlière; J Toullec; A Maillot; D Botta-Fridlund; A Gauthier
Journal:  Gastroenterol Clin Biol       Date:  1991

3.  [Fatal sub-fulminant hepatitis caused by cyproterone acetate. A new case].

Authors:  P Castellani; D Bernardini; C Renou; C Zamora; I Portal; A Gauthier; D Botta-Fridlund
Journal:  Gastroenterol Clin Biol       Date:  1996

4.  Fulminant hepatitis due to cyproterone acetate.

Authors:  H Lévesque; C Trivalle; N D Manchon; J P Vinel; N Moore; J Hémet; H Courtois; E Bercoff; J Bourreille
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

5.  [Fatal hepatitis caused by cyproterone acetate].

Authors:  L Bressollette; A Dubois; D Carlhant; C Morand; D Mottier; C Riche
Journal:  Therapie       Date:  1994 Mar-Apr       Impact factor: 2.070

Review 6.  Fatal fulminant hepatic failure due to cyproterone acetate.

Authors:  G Friedman; E Lamoureux; A H Sherker
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

7.  Unusually high alanine aminotransferase to aspartate aminotransferase ratio in a patient with cyproterone-induced icteric hepatitis.

Authors:  Yu-Chen Hsu; Dar-In Tai
Journal:  Chang Gung Med J       Date:  2011

Review 8.  Hepatotoxicity induced by cyproterone acetate: a report of three cases.

Authors:  Ioanna Savidou; Melanie Deutsch; Aspasia S Soultati; Dimitrios Koudouras; Georgia Kafiri; Spyridon P Dourakis
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

Review 9.  Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.

Authors:  Alison Birtle
Journal:  Expert Rev Anticancer Ther       Date:  2013-01       Impact factor: 4.512

10.  [Acute hepatic necrosis in a patient treated with cyproterone acetate].

Authors:  A Lombardi; P Ferrazza; F Castaldi; L Covotta; A Tesoriere; V Urbano; G Midiri
Journal:  G Chir       Date:  1998-04
View more
  4 in total

1.  Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription.

Authors:  Chunyan Luo; Elisabeth Pook; Bo Tang; Weiyi Zhang; Sisi Li; Kirsten Leineweber; Shing-Hu Cheung; Qiuyun Chen; Martin Bechem; Jing-Shan Hu; Volker Laux; Qing Kenneth Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-20       Impact factor: 5.187

Review 2.  Perioperative Considerations for Person-Centered Gender-Affirming Surgery.

Authors:  Luis E Tollinche; William E Rosa; Christian D van Rooyen
Journal:  Adv Anesth       Date:  2021-09-29

3.  SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people.

Authors:  A D Fisher; G Senofonte; C Cocchetti; G Guercio; V Lingiardi; M C Meriggiola; M Mosconi; G Motta; J Ristori; A M Speranza; M Pierdominici; M Maggi; G Corona; F Lombardo
Journal:  J Endocrinol Invest       Date:  2021-10-22       Impact factor: 4.256

4.  Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.

Authors:  Suzanne M E Kuijpers; Chantal M Wiepjes; Elfi B Conemans; Alessandra D Fisher; Guy T'Sjoen; Martin den Heijer
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.